Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 10:51:58 Source:healthViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Elvis' granddaughter Riley Keough fights Graceland estate auction
Next:Iran's nuclear policy unlikely to change even after president's death
You may also like
- Slovak Parliament votes to condemn political violence after assassination attempt on prime minister
- Rural Entrepreneur Helps Farmers Live Better Lives
- Street Vendor in SW China's Sichuan Wins Hearts with English Fluency
- ICU Nurse Devoted to Saving Lives
- New Zealand Black Caps fans look to Twenty20 World Cup with hope, trepidation
- Pic Story of Flower
- China sweeps 3 golds as badminton concludes at Hangzhou Asiad
- Policies yield key results in Xiong'an
- Garcia, Winker go deep as Nats end slide, beat struggling Twins 12